Preview Mode Links will not work in preview mode

Dec 10, 2019

Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination.

Based on a longitudinal field study of five projects in a leading pharmaceutical company,...


Nov 26, 2019

In this episode, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients.

Cell-based assays are vital tools in modern drug discovery. Live cell cultures that replicate in vivo physiological...


Nov 12, 2019

New immunotherapies that integrate innate and adaptive immune responses may increase efficacy against many cancers, and have the potential to expand the range of tumours and patients that can be treated with immunotherapy.

Over the past decade, insights into the molecular mechanisms that cancer cells use to evade...


Oct 29, 2019

In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated processes.

Many common lab procedures now run in parallel, miniaturised experiments – DNA synthesis, target screening, organoid...


Oct 15, 2019

Recently there have been attempts by small-to-medium sized pharmaceutical companies to create in-house, integrated platform-DDD (PD3) capabilities. This strategy does not come without risks, but has quietly been implemented to increase drug candidate efficacy/safety and pipeline numbers. In some cases this has resulted...